Key features and details
- Expression system: Escherichia coli
- Purity: > 90% SDS-PAGE
- Active: Yes
- Tags: His-DDDDK tag N-Terminus
- Suitable for: Functional Studies, SDS-PAGE
Product nameRecombinant Hepatitis C Virus Core 2a protein (Tagged)
Specific Activity: 93 pmole/min/μg
Assay conditions: Assay was done in 100 μl HCV assay buffer containing 50 mM Tris, pH7.4, 150 mM NaCl, 5 mM DTT, 10% glycerol, and 5 μM HCV substrate peptide. Reaction was monitored at room temperature for 20 min continuously at ex350/em500.
Purity> 90 % SDS-PAGE.
Expression systemEscherichia coli
Protein lengthProtein fragment
SequenceMDYKDDDDKHHHHHHGCVSIIGRLHVNGSGSITAYAQQTRGLLGAIVVSM TGRDRTEQAGEVQILSTVSQSFLGTTISGVLWTVYHGAGNKTLAGLRGPV TQMYSSAEGDLVGWPSPPGTKSLEPCKCGAVDLYLVTRNADVIPARRRGD KRGALLSPRPISTLKGSSGGPVLCPRGHVVGLFRAAVCSRGVAKSIDFIP VETLDVVTRS
Predicted molecular weight22 kDa including tags
TagsHis-DDDDK tag N-Terminus
Additional sequence informationFusion protein of amino acids 21-32 of NS4A, linker (4 amino acids) and amino acids 3-181 of NS3.
- Anti-DDDDK tag (Binds to FLAG® tag sequence) antibody (ab1162)
- Anti-DDDDK tag (Binds to FLAG® tag sequence) antibody (ab1257)
- Anti-6X His tag® antibody [HIS.H8] (ab18184)
- Anti-DDDDK tag (Binds to FLAG® tag sequence) antibody [F-tag-01] (ab18230)
- Anti-6X His tag® antibody [4D11] (ab5000)
- Anti-6X His tag® antibody (ab9108)
Our Abpromise guarantee covers the use of ab198063 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on Dry Ice. Store at -80°C. Avoid freeze / thaw cycle.
Constituents: 0.63% Tris HCl, 2.32% Sodium chloride, 0.2% Triton X-100, 0.08% Beta mercaptoethanol, 30% Glycerol (glycerin, glycerine)
100 µg/mL DDDDK peptide
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- Genome polyprotein
- HCV 2a
- HCV core 2a
RelevanceHCV (Hepatitis C Virus) viral core protein forms the internal viral coat that encapsidates the genomic RNA and is enveloped in a host cell-derived lipid membrane. The hepatitis C virus (HCV) core protein represents the first 177 amino acids of the viral precursor polyprotein and is cotranslationally inserted into the membrane of the endoplasmic reticulum. The N terminus of the core protein is involved in transcriptional repression. There are over 20 different subtypes of Hepatitis C Virus; the preponderance and distribution of HCV genotypes varies globally. HCV Genotype information is important because of the role it plays in predicting HCV medical treatment response and treatment duration. Sustained cure rates (sustained viral response) of 75% or better occur in people with genotypes HCV 2 and 3 in 24 weeks of treatment. Genotypes 1a and 1b, the most prevalent worldwide, have the poorest rates of response to the present treatment regimen, which is a combination of pegylated alfa interferon 2b with ribavirin. HCV core protein is among the most conserved proteins in HCV and is known to induce sensitization of cytotoxic T lymphocytes (CTL). Therefore, it is a prime candidate for a component of a potential HCV vaccine.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab198063 has not yet been referenced specifically in any publications.